China Fully Reopened but the COVID Wave Is Devastating Chemical Factories. What the January 2023 GACC Data and Production Reality on the Ground Actually Mean

GACC dropped the December 2022 trade numbers on 13 January and the headline looked survivable. Full-year exports landed at USD 3.59 trillion, up 7 per cent on 2021, a record. Scroll down one line and the December print told the real story: exports down 9.9 per cent year on year, the steepest monthly contraction since the February 2020 Wuhan shock. For chemicals specifically (HS Chapters 28, 29, 38, 39) the monthly number was worse still, and behind it sat the operational reality nobody at the press conference mentioned. China officially reopened borders on 8 January. The COVID wave that started when zero-COVID ended on 7 December was at that point eviscerating chemical production across Jiangsu, Shandong, and Zhejiang.

This is the gap that matters for your Q1 2023 planning. Headline reopening narrative says “back to business.” Ground truth says operating rates in the big continuous-process clusters are still 50 to 65 per cent of capacity through mid-January, with full normalisation unlikely before late February and almost certainly pushed by Spring Festival travel and the second wave it’ll detonate. If you booked Q1 orders against a late-2022 assumption, you’re looking at a six to ten week slip on delivery and a 9 to 13 per cent uplift on landed cost. The numbers get worse if your supplier is in Taixing, Zibo, or Dalian versus Huizhou or Nansha.

What follows is how we’re reading the GACC release, what the granular chemical-sector data actually shows, and the arithmetic on a real 80-tonne order moving through Ningbo to Port Botany in February.

What the 13 January GACC Release Actually Said

Strip the headline and the monthly data is ugly. December 2022 exports came in at USD 306.08 billion, down 9.9 per cent year on year in dollar terms, down 0.5 per cent in yuan terms (a reminder that the weak yuan is flattering everything). Imports fell 7.5 per cent in dollars. Trade surplus widened to USD 78 billion, but only because imports fell harder than exports, which is the signature of a demand collapse layered on top of a supply disruption, not a healthy surplus.

For the full year, the USD 3.59 trillion export figure was up 7 per cent. That looked fine until you break it by quarter. Q1 2022: +15.5 per cent. Q2: +12.5 per cent. Q3: +10.2 per cent. Q4: -6.8 per cent. The deceleration through the year is the zero-COVID lockdown arc layered onto weakening external demand. November was already down 8.7 per cent. December extended the trend. January and February 2023 will print worse, because CNY alone (spring festival fell 22 January) lops two to three weeks of factory output off the base, and the COVID wave is still running through workforces that had been shielded since 2020.

On chemicals specifically, the picture splits by sub-chapter. Organic chemicals (HS 29) held up better than average because a lot of that volume is commodity grade feedstock with contract lift obligations. Plastics in primary forms (HS 39) cratered, because that’s where spot volume and discretionary buying live. Specialty chemicals (HS 38) sat in the middle, with MDI and TDI down on Wanhua running at reduced rate out of Yantai and Ningbo, and surfactants holding up because the bulk of that production is in Guangdong which reopened earliest.

Read those figures against China’s reopening rhetoric. On 8 January, the National Immigration Administration resumed passport issuance for tourism. Hong Kong border checkpoints reopened. International arrivals no longer required five days of quarantine. That’s the diplomatic and travel reopening. The production reopening lags by six to twelve weeks, and the export data reopening (landed shipments into Australian and US ports) lags by another four to eight weeks on top because of the vessel transit and dwell time.

The Production Reality Behind the Headlines

By 12 January, we had direct read-outs from twenty-plus suppliers across Jiangsu, Shandong, Zhejiang, and Guangdong. The pattern was consistent enough to generalise.

Wanhua’s Yantai site, the largest MDI producer globally at roughly 3.1 million tonnes of nameplate capacity, was operating around 70 per cent with one train on planned turnaround and the other two affected by staffing absence. Sinopec Zhenhai Refining and Chemical was running its ethylene cracker at roughly 80 per cent but downstream EO/EG units at closer to 65 per cent, because that’s where QC and packaging labour concentrated. Formosa Ningbo, which sits across the strait from Taiwan, had held up better, running at roughly 85 per cent, partly because its workforce is more stable and partly because the Ningbo infection peak hit earlier than Shanghai.

The Shandong private clusters (the independent refineries and the Dongying and Zibo specialty chemical plants) were worst hit. Multiple sources put the operating rate there in the 50 to 60 per cent band for most of January, with some smaller specialty plants below 40 per cent. Shandong’s provincial CDC stopped publishing infection data on 15 December, so there’s no official fever-clinic curve, but the fact that Baidu search volume for “ibuprofen” in Shandong peaked on 28 December and remained elevated through 10 January tells you where the wave was sitting.

Trucking inside China, the hidden layer that every import plan rests on, was below normal well into mid-January. SCFI inland data and CTA (China Trucking Association) spot indicators showed utilisation at roughly 70 per cent of December 2021 levels through the first ten days of January. That’s the line that starves plants of feedstock even when they have staff, and it’s why the operating rate story is worse than the “return to work” headline suggests.

Landed Cost Arithmetic on an 80 MT Acrylate Monomer Order

Let’s put actual numbers on this. Assume you’re bringing in 80 MT of butyl acrylate, HS 2916.12, CAS 141-32-2, ex-Ningbo to Port Botany, loaded in IBCs in four 20-foot containers at nominal 20 MT each. Your reference point is a December 2022 order booked pre-reopening wave. Your February 2023 lift is the one at risk.

That’s USD 15,536 added to the same order over seven weeks, or 12.6 per cent on landed cost. Pull apart where the delta lives. FOB is up USD 105 per MT because plants are passing through their own operating deleverage on reduced run rates. Inland China nearly doubled because trucking is thin and drivers are still sick or stuck. Ocean freight is up USD 22 per MT because February space into Australia east coast has tightened as carriers cut blank sailings into the CNY period. Demurrage and detention accrual is the ugly line, up ten-fold, because documentation delays at origin (SGS cert issuance, CIQ release, bill of lading draft) are stacking five to twelve days on top of normal transit, and that eats into your free days at the destination port.

For US-bound buyers doing the same maths, replace the 5 per cent Australian duty with the HS 2916.12 base MFN of 4 per cent, add Section 301 List 3 at 25 per cent if you’re still on that list (butyl acrylate sits on List 3, tariff number 2916.12.00), add HMF at 0.125 per cent, MPF at 0.3464 per cent with the cap. That stack adds roughly USD 380 to USD 420 per MT against a non-China origin, which is why the sourcing decision tree keeps pointing at Taiwan, Korea, and the Gulf for anyone with List 3 exposure.

Three Planning Moves for the February-April Window

First move: assume your Q1 2023 orders are going to slip, and build the slip into your customer commitments now. If you normally run 60-day forward cover for downstream customers, you should be at 90 or 100 days for February and March delivery, funded through Q1 inventory build. The finance cost of carrying the extra stock at current rates is material but it’s a rounding error against the margin hit of being out of stock on a specialty line with no second source.

Second move: rework your supplier concentration. If more than 55 per cent of any single SKU volume comes out of Jiangsu or Shandong, that’s a concentration problem even in a normal year, and this is not a normal year. Start conversations now with Guangdong alternatives, with Taiwan (Formosa Plastics, Chang Chun, LCY Chemical), with Korean producers (LG Chem, Lotte Chemical, Hanwha), with Middle East (SABIC, Sadara, Tasnee). You don’t have to move volume, you have to open the relationship so that if Jiangsu slips a further four weeks in March, you have a call to make.

Third move: fix forward freight while it’s cheap. The Shanghai Containerised Freight Index (SCFI) China to Australia component was sitting at roughly 1,310 in mid-January, down more than 60 per cent from the July 2022 peak. Carriers are quoting six and twelve month contracts through mid-2023 at levels that look aggressive. When Chinese production recovers in Q2 and booking demand spikes into May-June, spot rates will move. Lock a contract now for 60 per cent of your expected Q2 volume, leave the rest on spot to capture further downside, and sleep better.

What the Data Will Look Like in March

The February GACC release, due mid-March, will combine January and February data into a single print because of CNY. That convention always dampens the signal, which suits the current political moment. Expect the combined January-February 2023 exports to land down somewhere between 6 and 11 per cent year on year, with chemicals weaker than the average and plastics weaker than chemicals. Imports will look relatively worse on the headline because of commodity price base effects (crude, iron ore, soybeans).

The granular data that matters for importers (monthly HS-level trade by destination, port throughput, container volumes) will show the real shape. China’s top ten chemical exports to Australia typically include HS 39 polyethylene, HS 39 PVC, HS 29 acrylonitrile, HS 28 titanium dioxide, HS 38 surfactants, HS 28 caustic soda, HS 29 phthalic anhydride, HS 29 melamine, HS 29 methanol, and HS 39 polypropylene. Track the monthly YoY on those ten and you’ll see the real production curve six to eight weeks before the aggregate data does.

The honest read of the 13 January release is that the headline FY2022 number is a rear-view mirror. The December monthly print is the first real chapter of a three-chapter story. Chapter two lands with the combined January-February data in mid-March and will be worse. Chapter three starts with the March data in late April and should, if the recovery curve plays out the way Guangdong’s did, show the first signs of normalisation. You need to plan your February to April landed cost, order book, and customer commitments against chapters two and three, not chapter one.

Book the inventory build, open the alternative supplier conversations, lock the forward freight, and rewrite the force majeure clause. The reopening is real, but the production base underneath it will not be ready to carry your orders until the second half of Q1 at the earliest. Don’t let the headline number make that decision for you.